Introduction

Colorectal cancer (CRC) is the third most common cancer worldwide [1, 2], and approximately one-third of the incidence is accounted for rectal cancer. Preoperative radiotherapy (RT) is used for a part of rectal cancer patients to reduce the risk of local recurrence or to enable surgery for initially nonresectable tumors. It can be given either as short-course RT or long-course chemoradiotherapy (CRT) with 5-fluorouracil (5-FU) depending on clinical staging. The latter is usually recommended for locally advanced rectal cancer [3].

However, the response to preoperative therapy in terms of tumor regression or disease outcome is
variable, and some patients might benefit from a more individualized risk-benefit assessment than is currently available [4–6]. Thus far, there are no clinical molecular markers that can aid in predicting response to (C)RT or enable stratifying patients into separate treatment groups according to their prognosis [3]. Therefore, various factors have been investigated in order to determine their predictive or prognostic potential regarding (C)RT. These factors include for example markers associated with cell proliferation, apoptosis, angiogenesis, inflammatory response, diverse oncogenic pathways, epithelial-mesenchymal transition, microsatellite instability, or the stem-cell nature of cancer cells [6–16].

CIP2A (cancerous inhibitor of PP2A) inhibits protein phosphatase 2A (PP2A) tumor suppressor activity and thereby promotes malignant cell transformation and tumor growth [17–19]. CIP2A is known to be overexpressed in several cancer types, and its overexpression has been demonstrated to associate with reduced survival for example in gastric cancer [20], serous ovarian carcinoma [21], nonsmall-cell lung carcinoma [22], chronic myeloid leukemia [23], CRC [24], and head and neck squamous cell carcinoma (HNSCC) [25]. CIP2A expression has also been linked to poorly differentiated histology in various cancers [18, 19, 26, 27]. CIP2A promotes several signaling pathways contributing to cell proliferation, apoptosis resistance, and senescence evasion. In addition to Myc, CIP2A-mediated inhibition of protein phosphatase 2A (PP2A) is known to stimulate Akt kinase and E2F transcription factor 1 (E2F1) pathways [18, 19]. In normal tissues, except testis, CIP2A is expressed only at a low level, and its inhibition does not impair normal development or viability in mice [19, 28].

In connection to irradiation, CIP2A expression has been previously studied in radioreistant testicular stem-cell population, where it is targeted by octamer-binding transcription factor 4 (Oct4). The cooperation of CIP2A and Oct4 was shown to contribute to radioresistance in HNSCC cell lines and tumorigenicity in HNSCC xenograft models [25]. Importantly, the in vivo relevance of CIP2A in mediating intestinal radioresistance was recently demonstrated when CIP2A was shown to physically interact with Myc and support Myc-mediated intestinal regeneration in response to irradiation in vivo [29].

In this study, we have examined the relationship between CIP2A expression and radiation response both by immunohistochemistry (IHC) in clinical samples collected from rectal cancer patients and in vitro by assessing the effects of CIP2A knockdown on cell survival in a CRC cell line exposed to radiation.

Material and Methods

Patients and tumor samples

The study population consisted of 210 rectal cancer patients with tumors located in either middle or distal rectum. They were operated at Turku University Hospital between 2000 and 2009. Representative formalin-fixed paraffin-embedded (FFPE) surgical specimens were retrieved from the archives of the Department of Pathology, Turku University Hospital, and full clinicopathologic data were retrospectively gathered from those patients. Superficial tumors operated by local excision were excluded from the study as well as tumors from patients with distant metastases at the time of diagnosis. Pretreatment biopsies from patients treated with preoperative radiotherapy were also collected but not included in the analyses due to the small number of samples (n = 10).

The patients received either short-course preoperative RT (n = 89, 42%), long-course preoperative (C)RT (n = 51, 24%), or no treatment before surgery (n = 70, 33%), according to common clinical recommendations [30]. The type of treatment was chosen based on preoperative tumor staging, which included computed tomography (CT) or magnetic resonance imaging (MRI) of the rectum, abdominal CT, and chest X-ray or CT.

Short-course RT consisted of a total dose of 25 Gy delivered over 5 days in 5 Gy fractions, and the patients were operated on the following week. Long-course RT was given in 1.8 Gy fractions to a total dose of 50.4 Gy over 6 weeks with (n = 43) or without (n = 8) chemotherapy, and the patients were operated five to 7 weeks after RT. Chemotherapy included either bolus 5-fluorouracil (5-FU, n = 5) or capecitabine (n = 38). The type of surgery was anterior resection among 113 (54%) patients and abdominoperineal resection among 94 patients (45%). Three patients (1%) were operated with low Hartmann’s procedure or other type of surgery. Lymphovascular invasion was found in 45 of 157 (29%) tumors. Patients with established high-risk features were treated with adjuvant chemotherapy.

Tumors were staged according to the TNM criteria applicable at the time of surgery [31]. Follow-up information was available for 206 patients. The median follow-up time was 74.5 months, and disease recurrence (local or distant) was observed among 67 patients (33%). The basic clinicopathologic characteristics are shown in Table 1.

The study was conducted in accordance with the Declaration of Helsinki and the Finnish legislation for the use of archived tissue specimens and associated clinical information. The clinical data were retrieved, and the histological samples were collected and analyzed with the endorsement of the National Supervisory Authority for Welfare and Health, Finland (Dnro 1709/32/300/02, May 13, 2002).
Evaluation of the tumor regression grade

Tumor regression after long-course (C)RT was determined by JS and EK according to a simplified classification based on Dworak and Rödel scales [32–35]. The response to RT was divided into three categories: poor (only minimal or no tumor regression), moderate (some detectable vital tumor cells or cell groups), or excellent response (very few or no detectable tumor cells).

Immunohistochemistry

The most optimal FFPE tissue samples were selected to obtain enough tumor material for analyses. Antigen retrieval was performed by heating the 5-μm sections in microwave oven in Target Retrieval buffer, pH 9.0 (Dako Denmark A/S, Glostrup, Denmark) twice for 7 min. The rabbit polyclonal CIP2A antibody [36] was diluted to 1:4000 in Antibody Diluent Buffer (Dako Denmark A/S, Glostrup, Denmark) and incubated for 1 h at RT. For detection, Dual Link System—HRP and DAB Chromogen System (Dako Denmark A/S, Glostrup, Denmark) were used. The stainings were performed with Lab Vision Autostainer.

Analysis of CIP2A expression

Tumor samples from 204 patients were included in the final analyses. Six tumors could not be reliably evaluated with IHC due to the limited amount of tumor cells. Two observers evaluated the cytoplasmic IHC staining of CIP2A blinded to clinical data (AE all samples and EB 40 samples). Tissue from normal testis was used as a positive control. Cytoplasmic staining was scored as negative (0), weak (1 + ), moderate (2 + ), or strong (3 + ). Strong staining intensity corresponded to the positive control, weak staining intensity was still distinguishable from the background, and moderate staining intensity was intermediate between these two. Representative immunostainings of CIP2A are shown in Figure 1.

For statistical analyses, the most intense cytoplasmic staining index (MICI) and average cytoplasmic staining index (ACI) were used to classify the samples into two subgroups according to the index value being either below or above median level [37]. The indices were calculated with the following formula: \[ I = 0 \times f_0 + 1 \times f_1 + 2 \times f_2 + 3 \times f_3 \], where \( I \) is the staining index and \( f_0–f_3 \) the fractions of cells (from 0 to 1) showing a defined level of staining. To obtain MICI, the area containing the most intense staining of cancer cells was chosen from each sample, and the fraction of cancer cells belonging to each staining intensity category was estimated from that area. ACI was calculated as an average of three randomly selected areas from which the fraction of cancer cells belonging to each staining intensity category was estimated. Theoretically, the indices could vary between 0 and 3. The samples were observed with 10× objective magnification.

Table 1. Patient characteristics (n = 210).

|                      | Short-course RT, n (%) | Long-course RT, n (%) | Control, n (%) |
|----------------------|------------------------|-----------------------|----------------|
| Sex                  |                        |                       |                |
| Male                 | 55 (45.5)              | 33 (27.3)             | 33 (27.3)      |
| Female               | 34 (38.2)              | 18 (20.2)             | 37 (41.6)      |
| Mean age (years)     | 65.3                   | 64.3                  | 73.9           |
| Median age (years)   | 68.0                   | 66.1                  | 74.1           |
| Range                | 34.3–82.0              | 41.9–81.2             | 47.0–92.3      |
| Preoperative T*      |                        |                       |                |
| T1-2                 | 27 (30.0)              | 0 (0)                 | 21 (30.0)      |
| T3                   | 54 (60.7)              | 2 (3.9)               | 12 (17.1)      |
| T4a                  | 1 (1.1)                | 46 (90.2)             | 3 (4.3)        |
| Tx                   | 7 (7.9)                | 1 (2.0)               | 34 (48.6)      |
| Postoperative T      |                        |                       |                |
| T1                   | 3 (3.4)                | 2 (3.9)               | 5 (7.1)        |
| T2                   | 32 (36.0)              | 7 (13.7)              | 26 (37.1)      |
| T3                   | 50 (56.2)              | 28 (54.9)             | 36 (51.4)      |
| T4†                  | 3 (3.4)                | 13 (25.5)             | 3 (4.3)        |
| T0                   | 1 (1.1)                | 1 (2.0)               | 0 (0)          |
| Postoperative N      |                        |                       |                |
| N0                   | 52 (58.4)              | 32 (62.7)             | 39 (55.7)      |
| N1                   | 25 (28.1)              | 14 (27.5)             | 16 (22.9)      |
| N2                   | 12 (13.5)              | 5 (9.8)               | 12 (17.1)      |
| Nx                   | 0 (0)                  | 0 (0)                 | 3 (4.3)        |
| Postoperative stage  |                        |                       |                |
| Stage I              | 26 (29.2)              | 5 (9.8)               | 25 (35.7)      |
| Stage II             | 26 (29.2)              | 27 (52.9)             | 17 (24.3)      |
| Stage III            | 36 (40.4)              | 18 (35.3)             | 28 (40.0)      |
| No vital tumor       | 1 (1.1)                | 1 (2.0)               | 0 (0)          |
| Postoperative grade  |                        |                       |                |
| G1                   | 9 (10.1)               | 10 (19.6)             | 13 (18.6)      |
| G2                   | 56 (62.9)              | 33 (64.7)             | 46 (65.7)      |
| G3                   | 22 (24.7)              | 3 (5.9)               | 11 (15.7)      |
| Gx                   | 2 (2.2)                | 5 (9.8)               | 0 (0)          |
| Circumferential margin (mm) |         |                       |                |
| 0                    | 3 (3.4)                | 8 (15.7)              | 4 (5.7)        |
| 0 ≤ CRM ≤ 2          | 8 (9.0)                | 9 (17.6)              | 7 (10.0)       |
| >2                   | 65 (73.0)              | 22 (43.1)             | 30 (42.9)      |
| Unknown              | 13 (14.6)              | 12 (23.5)             | 29 (41.4)      |
| Follow-up status     |                        |                       |                |
| Alive without disease| 56 (62.9)              | 19 (37.3)             | 30 (42.9)      |
| Alive with disease   | 2 (2.2)                | 3 (5.9)               | 4 (5.7)        |
| Died of disease      | 19 (21.3)              | 20 (39.2)             | 20 (28.6)      |
| Died of other causes | 12 (13.5)              | 9 (17.6)              | 16 (22.9)      |

RT, radiotherapy; CRM, circumferential resection margin.

*Includes T3 tumors with threatened circumferential margin involvement.
Cell culture experiments and irradiation studies

The RKO CRC cell line (ATCC® CRL-2577™) was purchased from ATCC (Manassas, VA). Cells were grown in Dulbecco’s minimal essential medium supplemented with 10% FBS, 2 mmol/L glutamine, and 1% penicillin/streptomycin.

Cells in the logarithmic growth phase were transfected with CIP2A or scrambled double-stranded small interfering RNAs (siRNA) using Oligofectamine (Invitrogen™, Thermo Fisher Scientific, Waltham, MA) according to the manufacturer’s instructions. The siRNA sequences have been previously published [26]. The cells were lysed in RIPA buffer, and CIP2A protein levels were analyzed by Western blotting with CIP2A antibody (2G10-3B5; Santa Cruz Biotechnology, Dallas, TX) as described previously [38]. HRP-conjugated anti-GAPDH mAb (mAbcam 9484; Abcam, Cambridge, UK) was used as a loading control.

Radiation experiments were performed using the 96-well clonogenic cell survival assay as previously described [39]. Forty-eight hours after the siRNA transfections, the cells were harvested into single-cell suspensions. The cells were irradiated at room temperature in separate Falcon tubes containing 25 000 cells/treatment in 6 mL culture medium (4167 cells/mL). The irradiation was performed at the radiotherapy department using a linear accelerator (Clinac 2100; Varian CA) with 6 MeV photon irradiation at a dose rate of 2 Gy/min.

After irradiation, the cells were further diluted into 50 mL culture medium in appropriate concentration and 200 μL of cell suspension/well was pipetted in duplicate into 96-well plates. The number of cells per well was adjusted according to the expected cell death as follows: control 2 cells/well, 0.75 Gy 3 cells/well, 1.25 Gy 4 cells/well, 2.5 Gy 8 cells/well, 5 Gy 20 cells/well, and 7.5 Gy 100 cells/well. The plates were incubated in the cell culture incubator until visible colonies were formed. The plates were examined using an inverted phase contrast microscope. Wells containing colonies of at least 32 cells were considered positive.

The surviving fractions (SF) were calculated with the formula:

$$SF = \frac{\text{no. of positive wells}}{\text{no. of plated cells in control}}$$

The survival curves of cancer cells were fitted using the linear quadratic (LQ) model (SF = exp[\(- (\alpha D + \beta D^2)\)]); D, radiation dose). The area under the curve (AUC) values were calculated with a numerical integration algorithm. The results were calculated from three experiments for each treatment with duplicate plates for each radiation dose.

Statistical analysis

Statistical analyses were performed with IBM SPSS Statistics for Windows, version 21.0 (IBM Corporation, Armonk, NY). Frequency table data were calculated with

Figure 1. Different CIP2A immunohistochemical cytoplasmic staining intensities in rectal adenocarcinomas. (A) Negative for CIP2A protein expression. (B) Weak (1 +) CIP2A protein expression. (C) Moderate (2 +) CIP2A protein expression. (D) Strong (3 +) CIP2A protein expression. Original objective magnification 20x.
CIP2A indicates resistance to radiotherapy in rectal cancer

E.-M. Birkman et al.

Results

CIP2A expression in relation to clinicopathologic variables

CIP2A MICI was found to associate with patient age at the time of diagnosis and with the depth of tumor invasion (pT). Low CIP2A MICI (median, cut-off 1.20) was more frequently observed among the younger patients (age ≤ median, cut-off 70 years; Fisher’s exact test, \( P = 0.023 \); OR 1.98, 95% CI: 1.13–3.47) and among patients with most invasive tumors (pT4 vs. pT1–pT2; Fisher’s exact test, \( P = 0.022 \)). No association was found between CIP2A MICI and patient sex, postoperative histological differentiation grade, lymph node status, postoperative stage, circumferential resection margin (CRM, 1 or 2 mm cut-off), or lymphovascular invasion (yes vs. no). Low CIP2A ACI (median, cut-off 0.94) was observed slightly more often among the well-differentiated tumors (Fisher’s exact test, \( P = 0.050 \)). The relationship of CIP2A MICI with selected clinicopathologic variables is presented in Table 2 and for CIP2A ACI in Table S1.

CIP2A expression in relation to tumor regression grade

CIP2A MICI in relation to tumor regression was evaluated in 47 samples from patients having received long-course (C)RT. Among patients who had moderate or excellent response to (C)RT, CIP2A MICI was more frequently below median than in the poorly responding group (Fisher’s exact test, \( P = 0.006 \); OR 14.7, 95% CI: 1.70–126.4). Similarly, low CIP2A ACI was associated with moderate or excellent treatment response (Fisher’s exact test, \( P = 0.007 \); RR 1.63, 95% CI: 1.20–2.20). Tumor regression in relation to CIP2A MICI is presented in Table 2 and in relation to CIP2A ACI in Table S1.

CIP2A expression in relation to survival

Patients with tumors having CIP2A MICI below median had higher 36-month disease-specific survival rate than patients with CIP2A above median when DSS was analyzed as a dichotomous variable (Fisher’s exact test, \( P = 0.014 \); OR 2.85, 95% CI: 1.23–6.59). (Table 2). A similar trend was also observed between low CIP2A expression and higher 36-month DSS rate in the case of CIP2A ACI (Fisher’s exact test, \( P = 0.060 \), Table S1). However, when using 60 months as a cut-off point, the survival difference between CIP2A MICI levels was no longer significant. No significant relationship was found between CIP2A MICI and DFS as a dichotomous variable using either 36 or 60 months as a cut-off point.

Table 2. Association of clinicopathologic variables of rectal cancer patients with CIP2A protein expression defined by the most intense cytoplasmic staining index (n = 204).

| CIP2A most intense cytoplasmic staining index | Below median, n (%) | Above median, n (%) | P-value* |
|---------------------------------------------|---------------------|---------------------|----------|
| Age                                         |                     |                     |          |
| ≤70 years                                    | 67 (57.8)           | 36 (40.9)           | 0.023    |
| >70 years                                    | 49 (42.2)           | 52 (59.1)           |          |
| Postoperative T†                             |                     |                     |          |
| pT1-2                                       | 36 (31.3)           | 37 (42.0)           | 0.022    |
| pT3                                         | 63 (54.8)           | 48 (54.5)           |          |
| pT4                                         | 16 (13.9)           | 3 (3.4)             |          |
| Post-treatment tumor regression‡            |                     |                     |          |
| Poor                                        | 15 (42.9)           | 11 (91.7)           | 0.006    |
| Moderate/ excellent                         | 20 (57.1)           | 1 (8.3)             |          |
| DSS§                                         |                     |                     |          |
| ≥36 months                                   | 95 (90.5)           | 60 (76.9)           | 0.014    |
| <36 months                                   | 10 (9.5)            | 18 (23.1)           |          |

*Pearson’s chi-squared or Fisher’s exact test.
†Excluding one tumor that could not be assessed for postoperative T.
‡Assessed only after long-course (chemo)radiotherapy.
§Disease-specific survival, alive versus death of disease.
In the univariate survival analysis, CIP2A MICI was not associated with DFS or DSS. The multivariate analysis for DSS was performed with the following covariates: CIP2A MICI (below vs. above median), RT treatment group (short RT or long (C)RT vs no treatment), sex (female vs. male), age (below vs. above median, 70 years as cut-off), postoperative nodal status (N1 or N2 vs. N0), the presence of lymphovascular invasion (yes vs. no), CRM ($\leq 2$ mm vs. $>2$ mm), and disease recurrence status (yes vs. no). The remaining factors predicting reduced DSS were CIP2A MICI above median ($P = 0.014$, HR 3.02, 95% CI: 1.26–7.26), age above 70 years ($P = 0.002$, HR 3.98, 95% CI: 1.65–9.59), long-course (C)RT ($P = 0.040$, HR 3.19, 95% CI 1.05–9.66), and disease recurrence ($P < 0.0001$, HR 291.8, 95% CI: 36.9–2307.1).

The multivariate analysis for DFS was performed with the same variables as DSS excluding disease recurrence status. CIP2A MICI did not remain as an independent predictive factor, whereas age above 70 years ($P = 0.026$, HR 1.80, 95% CI: 1.07–3.01) and postoperative nodal status N2 were predictive for reduced DFS ($P = 0.002$, HR 2.88, 95% CI: 1.48–5.62). Results from multivariate analyses are shown in Table 3.

**The effect of CIP2A knockdown on radiosensitivity**

The mean AUC values for CIP2A siRNA-transfected cells and scrambled control were 1.7 ± 0.1 Gy and 2.1 ± 0.1 Gy, respectively. The cells with CIP2A knockdown were significantly more sensitive to radiation than the control cells (paired t-test, $P = 0.015$). The cell survival curves from the irradiation experiments and corresponding Western blot results are presented in Figure 2.

**Discussion**

To our knowledge, the association between CIP2A expression and clinical response to radiotherapy has not been previously studied in rectal cancer. We have investigated CIP2A protein

| Table 3. Cox’s multivariate analysis for disease-free and disease-specific survival ($n = 138$)* |
|---------------------------------|---------------------------------|---------------------------------|---------------------------------|---------------------------------|---------------------------------|---------------------------------|
|                                | Number of patients  | Disease-free survival | Disease-specific survival |                                |                                |                                |
|                                |                   | $P$-value$^1$ | HR  | 95% CI | $P$-value$^1$ | HR  | 95% CI |
| Age                            |                   |                  |     |        |                  |     |        |
| $\leq 70$ years (ref)           | 63                | 0.026            | 1.80 | 1.07–3.01 | 0.002 | 3.98 | 1.65–9.59 |
| $>70$ years                    | 75                |                  |     |        |                  |     |        |
| Preoperative treatment group    |                   |                  |     |        |                  |     |        |
| Short-course RT                | 69                | 0.331            | 0.73 | 0.39–1.37 | 0.783 | 1.15 | 0.42–3.13 |
| Long-course (C)RT              | 31                | 0.431            | 1.31 | 0.67–2.59 | 0.040 | 3.19 | 1.05–9.66 |
| No (C)RT (ref)                 | 38                |                  |     |        |                  |     |        |
| CIP2A MICI                     |                   |                  |     |        |                  |     |        |
| $\leq$Median (ref)             | 78                | 0.966            | 0.99 | 0.56–1.73 | 0.014 | 3.02 | 1.26–7.26 |
| $>Median$                      | 60                |                  |     |        |                  |     |        |
| Disease recurrence             |                   |                  |     |        |                  |     |        |
| Yes                            | 39                |                  |     |        |                  |     |        |
| No (ref)                       | 99                |                  |     |        |                  |     |        |
| Postoperative N                |                   |                  |     |        |                  |     |        |
| N1                             | 35                | 0.180            | 1.49 | 0.83–2.65 | 0.831 | 1.11 | 0.43–2.83 |
| N2                             | 19                | 0.002            | 2.88 | 1.48–5.62 | 0.945 | 1.05 | 0.30–3.60 |
| N0 (ref)                       | 84                |                  |     |        |                  |     |        |
| Sex                            |                   |                  |     |        |                  |     |        |
| Female                         | 62                | 0.200            | 0.70 | 0.40–1.21 | 0.473 | 0.75 | 0.35–1.63 |
| Male (ref)                     | 76                |                  |     |        |                  |     |        |
| Lymphovascular invasion        |                   |                  |     |        |                  |     |        |
| Yes                            | 43                | 0.071            | 1.63 | 0.96–2.77 | 0.666 | 1.19 | 0.54–2.62 |
| No (ref)                       | 95                |                  |     |        |                  |     |        |
| CRM                            |                   |                  |     |        |                  |     |        |
| $\leq 2$ mm                    | 35                | 0.230            | 1.40 | 0.81–2.43 | 0.297 | 1.47 | 0.71–3.02 |
| $>2$ mm (ref)                  | 103               |                  |     |        |                  |     |        |

CI, confidence interval; CRM, circumferential resection margin; (C)RT, (chemo)radiotherapy; HR, hazard ratio; MICI, most intense cytoplasmic staining index; N, lymph node status; ref, reference.

*Complete data for all the covariates were available for 138 patients.

$^1$Cox regression test.

$P$-values < 0.05 (in bold) are considered statistically significant.
levels in rectal adenocarcinomas from patients receiving either short- or long-course preoperative (chemo)radiotherapy or no treatment before surgery. As the majority of rectal tumors have been shown to overexpress CIP2A [40], we chose to use the most intense cytoplasmic staining index (MICI) together with the average cytoplasmic staining index (ACI) instead of only a dichotomous positive vs. negative IHC scoring system. In the long-course (C)RT group, patients with low-CIP2A-expressing tumors were more likely to respond to preoperative treatment as compared to those with high-CIP2A-expressing tumors. This was supported by the observation that transfection of RKO CRC cells with CIP2A siRNA sensitized them to irradiation and decreased their survival.

Our results are in agreement with previous findings demonstrating a role for CIP2A in promoting intestinal progenitor cell resistance to irradiation and other DNA-damaging therapies [29]. High CIP2A expression has been found to contribute to radioresistance in HNSCC cells [25], whereas CIP2A immunonegative tumors have been shown to respond favorably to cancer therapies [19, 21]. Additionally, the depletion of CIP2A transcription by siRNA has been found to significantly increase radiosensitivity in cervical squamous cell carcinoma and hepatocellular carcinoma cell lines [41].

In this study, low CIP2A expression was found to be more common among the most invasive tumors (pT4) than high CIP2A expression. Still, low CIP2A expression level was associated with better treatment response, defined by tumor regression grade, after long-course (C)RT. Low CIP2A expression level was also found to be linked with higher 36-month DSS rate of the patients in categorical analysis. Although CIP2A MICI was not associated with survival in the univariate Kaplan–Meier analysis, low CIP2A expression level was found to remain as an independent prognostic factor for increased DSS together with younger age and nonrecurrent disease, while having received long-course (C) RT as preoperative therapy was associated with reduced DSS. A prognostic role of CIP2A is also supported by several previous studies, which have found an association between low CIP2A expression and increased survival [27].

In CRC, studies investigating CIP2A as a prognostic biomarker have yielded variable results. In one study, no significant difference was found in five-year DSS between patients having tumors with either weak or strong CIP2A immunostaining. The survival difference remained statistically nonsignificant even when tumors of colon and rectum were examined separately [40]. In contrast, high CIP2A mRNA levels have been associated with reduced overall survival (OS) among CRC patients [24]. A similar relationship has been observed between strong CIP2A protein expression and reduced OS in KRAS wild-type CRC patients after surgical treatment of liver metastases [42].

In this study, CIP2A expression levels before and after preoperative treatment could not be compared because an adequate number of representative pretreatment biopsies were not available. At the time of diagnosis, biopsy material was not required for molecular pathology and thus often obtained in too small amounts for further analyses. However, it would be of interest to study whether the initial pretreatment CIP2A expression level or the magnitude of change in CIP2A expression during (C)RT also associates with radiation response. CIP2A expression after irradiation has been studied in vivo in mouse testis where its transcription or expression levels did not significantly change over the 144-h observation period [25]. This could support the hypothesis that initially low CIP2A expression might result in more pronounced response to preoperative (C)RT. Additionally, our finding that the knockdown of CIP2A expression by siRNA increases the radiosensitivity

Figure 2. (A) The cell survival curves from the irradiation experiments show the mean surviving fraction ±SE for each radiation dose. The RKO cells treated with CIP2A siRNA (black) were more sensitive to radiation (mean AUC 1.7 ± 0.1 Gy) than the control cells treated with scrambled siRNA (gray) (mean AUC 2.1 ± 0.1 Gy; paired t-test, \( P = 0.015 \)). (B) The corresponding Western blot demonstrates the reduction in CIP2A protein expression in siRNA-treated cells (siCIP2A) in comparison with scrambled siRNA-treated cells (siSCR) and nontreated control cells (contr). GADPH was used as a loading control.
of CRC cells in vitro implies that there could be a causal connection between the level of CIP2A expression and radiation response. In conclusion, our results suggest that low CIP2A protein expression level is associated with a favorable response to long-course (C)RT and with increased disease-specific survival in rectal cancer. This connection between reduced CIP2A expression and radiosensitivity was further demonstrated in cell irradiation experiments. Thus, the validity of CIP2A as a predictive biomarker for preoperative treatment response in rectal cancer warrants further investigation in the pursuit of providing more personalized treatment modalities for rectal cancer patients.

**Acknowledgments**

We thank Ms Sinikka Kollanus for preparing the tissue sections for IHC and Mr Jaakko Liippo for help with the pictures. This study was supported by the Turku University Foundation, the National Agency for Scientific Research, Tripoli, Libya; Sigrid Juselius Foundation and Foundation of Finnish Cancer Institute. The funders had no role in study design, data collection and analysis, and decision to publish or preparation of the manuscript.

**Conflict of Interest**

The authors declare that they have no competing interests.

**References**

1. Bray, F., J. S. Ren, E. Masuyer, and J. Ferlay. 2013. Global estimates of cancer prevalence for 27 sites in the adult population in 2008. Int. J. Cancer 132:1133–1145.
2. Ferlay, J., I. Soerjomataram, M. Ervik, R. Dikshit, S. Eser, C. Mathers, M. Reboiro, et al. 2013. GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11. International Agency for Research on Cancer, Lyon, France. Available via http://globoCAN.iarc.fr, accessed on 2 October 2017.
3. Glimelius, B., E. Tiret, A. Cervantes, and D. Arnold. 2013. Rectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 24(Suppl 6):vi81–vi88.
4. Folkesson, J., H. Birgisson, L. Pálhlman, B. Cedermark, B. Glimelius, and U. Gunnarsson. 2005. Swedish Rectal Cancer Trial: long lasting benefits from radiotherapy on survival and local recurrence rate. J. Clin. Oncol. 23:5644–5650.
5. Peeters, K. C., C. A. Marijnen, I. D. Nagtegaal, E. K. Kränenbarg, H. Putter, T. Wiggers, et al. 2007. The TME trial after a median follow-up of 6 years: increased local control but no survival benefit in irradiated patients with resectable rectal carcinoma. Ann. Surg. 246:693–701.
6. Shin, J. S., T. G. Tut, V. Ho, and C. S. Lee. 2014. Predictive markers of radiotherapy-induced rectal cancer regression. J. Clin. Pathol. 67:859–864.
7. Ghadimi, B. M., M. Grade, M. J. Difilippantonio, S. Varma, R. Simon, C. Montagna, et al. 2005. Effectiveness of gene expression profiling for response prediction of rectal adenocarcinomas to preoperative chemoradiotherapy. J. Clin. Oncol. 23:1826–1838.
8. Bao, S., Q. Wu, R. E. McLendon, Y. Hao, Q. Shi, A. B. Hjelmeland, et al. 2006. Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature 444:756–760.
9. Watanabe, T., Y. Komuro, T. Kiyomatsu, T. Kanazawa, Y. Kazama, J. Tanaka, et al. 2006. Prediction of sensitivity of rectal cancer cells in response to preoperative radiotherapy by DNA microarray analysis of gene expression profiles. Can. Res. 66:3370–3374.
10. Negri, F. V., N. Campanini, R. Camisa, F. Pucci, S. Bui, G. Cecconi, et al. 2008. Biological predictive factors in rectal cancer treated with preoperative radiotherapy or radiochemotherapy. Br. J. Cancer 98:143–147.
11. Kuremsky, J. G., J. E. Tepper, and H. L. McLeod. 2009. Biomarkers for response to neoadjuvant chemoradiation for rectal cancer. Int. J. Radiat. Oncol. Biol. Phys. 74:673–688.
12. Agostini, M., K. P. Janssen, I. J. Kim, E. D’Angelo, S. Pizzini, A. Zangrando, et al. 2015. An integrative approach for the identification of prognostic and predictive biomarkers in rectal cancer. Oncotarget 6:32561–32574.
13. Carpinetti, P., E. Donnard, F. Bettoni, P. Asprino, F. Koyama, A. Rozanski, et al. 2015. The use of personalized biomarkers and liquid biopsies to monitor treatment response and disease recurrence in locally advanced rectal cancer after neoadjuvant chemoradiation. Oncotarget 6:38360–38371.
14. Chang, L., P. Graham, J. Hao, J. Ni, J. Deng, J. Bucci, et al. 2015. Cancer stem cells and signaling pathways in radioresistance. Oncotarget 7:11002–11017.
15. Lim, S. H., W. Chua, C. Henderson, W. Ng, J. S. Shin, L. Chantrill, et al. 2015. Predictive and prognostic biomarkers for neoadjuvant chemoradiotherapy in locally advanced rectal cancer. Crit. Rev. Oncol. Hematol. 96:67–80.
16. Molinari, C., F. Matteucci, P. Caroli, and A. Passardi. 2015. Biomarkers and molecular imaging as predictors of response to neoadjuvant chemoradiotherapy in patients with locally advanced rectal cancer. Clin. Colorectal Cancer 14:227–238.
17. Junttila, M. R., P. Puustinen, M. Niemelä, R. Ahola, H. Arnold, T. Böttzauw, et al. 2007. CIP2A inhibits PP2A in human malignancies. Cell 130:51–62.
18. Khanna, A., J. E. Pimanda, and J. Westermarck. 2013. Cancerous inhibitor of protein phosphatase 2A, an emerging human oncoprotein and a potential cancer therapy target. Can. Res. 73:6548–6553.
CIP2A indicates resistance to radiotherapy in rectal cancer

E.-M. Birkman et al.

19. Laine, A., H. Sihto, C. Côme, M. T. Rosenfeldt, A. Zwolinska, M. Niemelä, et al. 2013. Senescence sensitivity of breast cancer cells is defined by positive feedback loop between CIP2A and E2F1. Cancer Discov. 3:182–197.
20. Khanna, A., C. Böckelman, A. Hemmes, M. R. Junttila, J. P. Wiksten, M. Lundin, et al. 2009. MYC-dependent regulation and prognostic role of CIP2A in gastric cancer. J. Natl Cancer Inst. 101:793–805.
21. Böckelman, C., H. Lassus, A. Hemmes, A. Leminen, J. Westermarck, C. Haglund, et al. 2011. Prognostic role of CIP2A expression in serous ovarian cancer. Br. J. Cancer 105:989–995.
22. Dong, Q. Z., Y. Wang, X. J. Dong, Z. X. Li, Z. P. Tang, Q. Z. Cui, et al. 2011. CIP2A is overexpressed in non-small cell lung cancer and correlates with poor prognosis. Ann. Surg. Oncol. 18:857–865.
23. Lucas, C. M., R. J. Harris, A. Giannoudis, M. Copland, J. R. Slupsky, and R. E. Clark. 2011. Cancerous inhibitor of PP2A (CIP2A) at diagnosis of chronic myeloid leukemia is a critical determinant of disease progression. Blood 117:6660–6668.
24. Wiegering, A., C. Pfann, F. W. Utbe, C. Otto, L. Ryczak, U. Máder, et al. 2013. CIP2A influences survival in colon cancer and is critical for maintaining Myc expression. PLoS One 8:e75292.
25. Ventelä, S., E. Sittig, L. Mannermaa, J. A. Mäkelä, J. Kulmala, E. Löyttyniemi, et al. 2015. CIP2A is an Oct4 target gene involved in head and neck squamous cell cancer oncogenicity and radioresistance. Oncotarget 6:144–158.
26. Côme, C., A. Laine, M. Chanrion, H. Edgren, E. Mattila, X. Liu, et al. 2009. CIP2A is associated with human breast cancer aggressivity. Clin. Cancer Res. 15:5092–5100.
27. Khanna, A., and J. E. Pimanda. 2016. Clinical significance of cancerous inhibitor of protein phosphatase 2A in human cancers. Int. J. Cancer 138:529–532.
28. Ventelä, S., C. Côme, J. A. Mäkelä, R. M. Hobbs, L. Mannermaa, M. Kallajoki, et al. 2012. CIP2A promotes proliferation of spermatogonial progenitor cells and spermatogenesis in mice. PLoS ONE 7:e33209.
29. Myant, K., X. Qiao, T. Halonen, C. Côme, A. Laine, M. Jahngborhan, et al. 2015. Serine 62-phosphorylated MYC associates with nuclear lamins and its regulation by CIP2A is essential for regenerative proliferation. Cell Rep. 12:1019–1031.
30. Glimelius, B., L. Påhlman, and A. Cervantes. 2010. Rectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 21(Suppl 5):v82–v86.
31. Sobin, L. H., and C. Wittekind. 2002. Colon and rectum. Pp. 72–76 in L. H. Sobin, C. Wittekind, eds. TNM classification of malignant tumours, 6th ed. UICC. Wiley, New York, NY.
32. Dworak, O., L. Keilholz, and A. Hoffmann. 1997. Pathological features of rectal cancer after preoperative radiochemotherapy. Int. J. Colorectal Dis. 12:19–23.
33. Rödel, C., P. Martus, T. Papadopoulos, L. Füzesi, M. Klimpfinger, R. Fietkau, et al. 2005. Prognostic significance of tumor regression after preoperative chemoradiotherapy for rectal cancer. J. Clin. Oncol. 23:8688–8696.
34. Korkeila, E., K. Talvinen, P. M. Jaakkola, H. Minn, K. Syrjänä, J. Sundström, et al. 2009. Expression of carbonic anhydrase IX suggests poor outcome in rectal cancer. Br. J. Cancer 100:874–880.
35. Avoranta, S. T., E. A. Korkeila, K. J. Syrjänä, S. O. Pyrhönä, and J. T. Sundström. 2012. Lack of CD44 variant 6 expression in rectal cancer invasive front associates with early recurrence. World J. Gastroenterol. 18:4549–4556.
36. Soo Hoo, L., J. Y. Zhang, and E. K. Chan. 2002. Cloning and characterization of a novel 90 kDa ‘companion’ auto-antigen of p62 overexpressed in cancer. Oncogene 21:5006–5015.
37. Lipponen, P., and Y. Collan. 1992. Simple quantitation of immunohistochemical staining positivity in microscopy for histopathology routine. Acta Stereol. 11:125–132.
38. Ålars, A., T. Avoranta, P. Österlund, M. Lintunen, J. Sundström, T. Jokilehto, et al. 2014. Heterogeneous EGFR gene copy number increase is common in colorectal cancer and defines response to anti-EGFR therapy. PLoS One 9:e99590.
39. Peckola-Heino, K., J. Kulmala, S. Grénman, T. E. Carey, and R. Grénman. 1989. Radiation response of vulvar squamous cell carcinoma (UM-SCV-1A, UM-SCV-1B, UM-SCV-2, and A-431) cells in vitro. Can. Res. 49:4876–4878.
40. Böckelman, C., S. Koskensalo, J. Haggström, M. Lundin, A. Ristimäki, and C. Haglund. 2012. CIP2A overexpression is associated with c-Myc expression in colorectal cancer. Cancer Biol. Ther. 13:289–295.
41. Huang, C., C. Wei, K. Chen, H. Chen, A. Cheng, and K. Chen. 2012. Bortezomib enhances radiation-induced apoptosis in solid tumors by inhibiting CIP2A. Cancer Lett. 317:9–15.
42. Chen, K. F., C. C. Yen, J. K. Lin, W. S. Chen, S. H. Yang, J. K. Jiang, et al. 2015. Cancerous inhibitor of protein phosphatase 2A (CIP2A) is an independent prognostic marker in wild-type KRAS metastatic colorectal cancer after colorectal liver metastasectomy. BMC Cancer 15:301.

Supporting Information
Additional supporting information may be found in the online version of this article:
Table S1. Association of clinicopathologic variables of rectal cancer patients with CIP2A protein expression defined by the average cytoplasmic staining index (n = 198).